AngioDynamics, Inc. (ANGO) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

Earnings Reports

• AngioDynamics (ANGO) Q4 2026: MedTech Share Hits 48%, Underpinning 18% Segment Growth
  July 14, 2026
• AngioDynamics (ANGO) Q3 2026: MedTech Revenue Jumps 19% as Portfolio Shift Accelerates
  April 02, 2026
• AngioDynamics (ANGO) Q2 2026: MedTech Mix Hits 45% of Sales, Accelerating Margin Expansion
  January 06, 2026
• AngioDynamics (ANGO) Q1 2026: MedTech Mix Reaches 47% as Mechanical Thrombectomy Grows 41%
  October 02, 2025
• AngioDynamics (ANGO) Q4 2025: MedTech Revenue Jumps 22% as Platform Transformation Accelerates
  July 17, 2025
• AngioDynamics (ANGO) Q3 2025: MedTech Surges 22% as AlphaVac Adoption Accelerates
  July 06, 2025
• AngioDynamics (ANGO) Q1 2025: MedTech Mix Hits 41% of Revenue, Powering Margin Shift
  October 03, 2024
• AngioDynamics (ANGO) Q4 2024: MedTech Share Doubles to 39% as Platform Expansion Accelerates
  July 16, 2024
• AngioDynamics (ANGO) Q3 2024: MedTech Revenue Climbs 13% as Portfolio Streamlines for Margin Upside
  April 04, 2024
• AngioDynamics (ANGO) Q2 2024: $15M Cost Takeout Targets FY27 Profitability Amid Thrombectomy Softness
  January 05, 2024

Browse all companies